AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

REDWOOD CITY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- AirNexis Therapeutics, Inc. ("AirNexis"), a clinical-stage biotech company developing therapeutics for pulmonary diseases, today announced results from a Phase 2b study of AN01, a dual PDE3/4 inhibitor DPI. The study, HSK39004-T1-202, was conducted in China by AirNexis' partner Haisco Pharmaceutical Group ("Haisco"). The Phase 2b study enrolled patients with chronic obstructive pulmonary disease (COPD) receiving background therapy of single or dual bronchodilator maintenance therapy who remained symptomatic despite such treatment. Data were presented earlier today at the 2026 European Respiratory Society (ERS) Congress in Barcelona, Spain. The ePoster will be available on the conference's website. AirNexis licensed AN01 (HSK39004 in China) from Haisco, which is developing the asset for the Greater China market; AirNexis holds development rights outside China.